How Analysts Rated Vitamin Shoppe, Inc. (NYSE:VSI) Last Week?

April 22, 2018 - By Nellie Frank

Vitamin Shoppe, Inc. (NYSE:VSI) Logo

Vitamin Shoppe, Inc. (NYSE:VSI) Ratings Coverage

Among 2 analysts covering Vitamin Shoppe (NYSE:VSI), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Vitamin Shoppe had 3 analyst reports since November 9, 2017 according to SRatingsIntel. On Thursday, November 9 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm earned “Equal-Weight” rating on Thursday, November 9 by Barclays Capital. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, February 28. Below is a list of Vitamin Shoppe, Inc. (NYSE:VSI) latest ratings and price target changes.

28/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $4 New Target: $3.75 Maintain
09/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $6 New Target: $3 Maintain
09/11/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $7.5 New Target: $4 Maintain

The stock increased 3.19% or $0.15 during the last trading session, reaching $4.85. About 241,704 shares traded. Vitamin Shoppe, Inc. (NYSE:VSI) has declined 77.86% since April 22, 2017 and is downtrending. It has underperformed by 89.41% the S&P500.

Vitamin Shoppe, Inc., through its subsidiaries, operates as a multi-channel specialty retailer and contract maker of nutritional products in the United States and internationally. The company has market cap of $117.39 million. It operates through three divisions: Retail, Direct, and Manufacturing. It currently has negative earnings. The firm provides custom manufacturing and private labeling services for VMS products, as well as develops and markets own branded products.

Vitamin Shoppe, Inc. (NYSE:VSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: